EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

177Lu-PSMA for prostate cancer: progress, challenges and future perspectives

Zhen Xi, Shi-Yu Ji, Yu Zhang, Ming-Hui Sun, Gao-Zhen Jia, Qi Jiang

Asian Journal of Andrology · 2026

DOI: 10.4103/aja2025103 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Asian Journal of Andrology, 2026. Verfasst von Zhen Xi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China. Hauptthemen laut MEDLINE: Lutetium, Radioisotopes, Radiopharmaceuticals, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer is a malignant tumor posing significant threats to the health of men worldwide. In advanced stages, it frequently progresses to castration-resistant prostate cancer, which is characterized by complex mechanisms and poor prognosis. In such cases, conventional treatments have limited effectiveness. However, the emergence of radionuclide therapy has provided new hope. Lutetium-177-labeled prostate-specific membrane antigen ( 177 Lu-PSMA), currently the most promising radioligand in clinical research, received approval from the U.S. Food and Drug Administration (FDA) in 2022. This review comprehensively summarizes recent advancements, efficacy assessments, and safety evaluations of 177 Lu-PSMA therapy. Additionally, we analyze its current limitations and suggest future research directions for PSMA-targeted radioligand therapy (RLT). Undoubtedly, 177 Lu-PSMA-617 is transforming metastatic castration-resistant prostate cancer (mCRPC) treatment. However, challenges remain regarding its potential standardization for use in non-mCRPC cases, the optimal treatment sequence, standardized imaging/molecular biomarkers, and toxicity management, all of which require further prospective validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LutetiumRadioisotopesRadiopharmaceuticalsProstatic Neoplasms, Castration-ResistantDipeptidesProstatic NeoplasmsAntigens, SurfaceHeterocyclic Compounds, 1-RingHumansMale

Stichwörter der Autor:innen

biomarkersclinical trialscombination therapyprecision medicineprostate cancerradioligand therapyradiopharmaceuticals

Substanzen

LutetiumRadioisotopesRadiopharmaceuticalsLutetium-177DipeptidesAntigens, SurfaceHeterocyclic Compounds, 1-Ring

Autor:innen und Institutionen

  • Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.

Zitieren

APA

Xi, Z., Ji, S. Y., Zhang, Y., Sun, M. H., Jia, G. Z., & Jiang, Q. (2026). 177Lu-PSMA for prostate cancer: progress, challenges and future perspectives. Asian Journal of Andrology. https://doi.org/10.4103/aja2025103

Vancouver

Xi Z, Ji SY, Zhang Y, Sun MH, Jia GZ, Jiang Q. 177Lu-PSMA for prostate cancer: progress, challenges and future perspectives. Asian Journal of Andrology. 2026. doi:10.4103/aja2025103

BibTeX
@article{Xi2026,
  author = {Xi, Zhen and Ji, Shi-Yu and Zhang, Yu and Sun, Ming-Hui and Jia, Gao-Zhen and Jiang, Qi},
  title = {177Lu-PSMA for prostate cancer: progress, challenges and future perspectives},
  journal = {Asian Journal of Andrology},
  year = {2026},
  doi = {10.4103/aja2025103}
}
Kostenlos starten →